Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AkaRx Inc.

Division of Dova Pharmaceuticals Inc.
www.akarx.com

Latest From AkaRx Inc.

US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed

Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels. 
Pricing Debate Approvals

Deal Watch: Opportunity Knocks For Partnerships In Asia

ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.

Deals Business Strategies

2016 Review: Refocus, Reduce, Reform The Watchwords In Japan

While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.

Japan Commercial

2016 Review: Price Pressure Marks A Turbulent Year In Japan

If one theme dominated the Japanese pharma market in 2016 it was reimbursement pricing, with the regular price cuts in April being followed by political pressure over high-priced oncology drugs, and then major new reforms by the end of the year.

Japan Policy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Dova Pharmaceuticals Inc.
  • Senior Management
  • Robert E Desjardins, Pres. & CEO
    Carol Braun Trapnell, MD, Head, Clinical R&D
    Donna L Tempel, COO
  • Contact Info
  • AkaRx Inc.
    Phone: (201) 909-3000
    South 61 Paramus Road
    4th Floor
    Paramus, NJ 07652
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register